Regulation of CCL18 by Corticosteroids in Severe Asthma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03779152

Acronym

CCL18

Enrollment

Registered

2018-12-19

Start date

2009-02-28

Completion date

2017-02-28

Last updated

2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The majority of asthmatic patients are well controlled by inhaled corticosteroid treatment, however some severe asthma resist this treatment. CCL18 is a target gene for corticosteroids and its dysfunction may correlate with phenotypes of asthma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. control subjects = * non-atopic and non-smoking * cutting to negative pneumoallergens, * Total IgE levels less than 100 ku / L * no clinical history of asthma * without background treatment 2. patients with intermittent asthma = * being asymptomatic between asthma attacks, * with symptoms less than once a week * having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical. * treated by ß2 mimetics on demand and will not have inhaled corticosteroids. 3. severe asthma insensitive to corticosteroid therapy = * continuous or nearly continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\] airway obstruction fixed with FEV1 ranging from less than 15% after 7 days of oral corticosteroid therapy to 40 mg / day of prednisolone; * Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited. 4. Severe corticosensitive asthma = continuous or near continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)\] * reversibility of FEV1 after treatment with oral corticosteroids. * Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited. 5. controlled moderate asthma treated with inhaled corticosteroids \<1500μg equivalent of beclomethasone dipropionate and with: ß2 long-acting mimetics (or anti-leukotriene, or theophylline) for at least 6 months.

Exclusion criteria

* existence of a chronic inflammatory pathology other than asthma * active smoking * pregnant or lactating women * have received oral corticosteroid treatment in the previous 3 weeks, * have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks.

Design outcomes

Primary

Measure	Time frame
Correlation between CCL18 rate and asthma phenotypes by elisa test	Baseline: one session

Countries

France

Outcome results